Proprietary technology addressing the rx-to-otc switch self-care market valued at over $38 billion annually

Working to identify quantum computing partnerships to strengthen our ai technology to include critical health records to better enable rx to otc switch candidates across multiple indications new york, ny / accesswire / december 17, 2024 / petros pharmaceuticals, inc. (nasdaq:ptpi) ("petros" or the "company"), a company focused on expanding consumer access to medication through over the counter ("otc") drug development programs, today announces a shift in its corporate strategy to focus on the development of its proprietary technology platform as a prospective rx-to-otc switch solution across a multitude of conditions and existing rx only therapies. if this software as a service ("saas") and software as a medical device (samd) concept is ultimately approved by the fda, it could significantly serve the emerging self-care market currently estimated to be valued over $38 billion with an expected compounded annual growth rate of 5.6% over the next 10 years.
PTPI Ratings Summary
PTPI Quant Ranking